De Mulder P - Search Results

1

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J. Bleumer I, et al. Among authors: de mulder p. Br J Cancer. 2004 Mar 8;90(5):985-90. doi: 10.1038/sj.bjc.6601617. Br J Cancer. 2004. PMID: 14997194 Free PMC article. Clinical Trial.

2

Immunotherapy for renal cell carcinoma.

Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Bleumer I, et al. Among authors: de mulder p. Eur Urol. 2003 Jul;44(1):65-75. doi: 10.1016/s0302-2838(03)00191-x. Eur Urol. 2003. PMID: 12814677 Review.

3

A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.

Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S, Mala C, Ullrich S, Mulders P. Varga Z, et al. Among authors: de mulder p. Folia Biol (Praha). 2003;49(2):74-7. Folia Biol (Praha). 2003. PMID: 12779016 Clinical Trial.

4

The role of adjuvant immunotherapy in renal cell carcinoma.

Mulders PF, De Mulder PH. Mulders PF, et al. Curr Urol Rep. 2002 Feb;3(1):44-9. doi: 10.1007/s11934-002-0010-y. Curr Urol Rep. 2002. PMID: 12084219 Review.

5

Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ. Brouwers AH, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3953S-60S. Clin Cancer Res. 2003. PMID: 14506194

6

The role of adjuvant therapy in non-metastatic RCC.

Bleumer I, de Mulder PH, Mulders PF. Bleumer I, et al. Can J Urol. 2006 Apr;13 Suppl 2:57-62. Can J Urol. 2006. PMID: 16672131 Review.

7

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF. Oosterwijk-Wakka JC, et al. J Immunother. 2002 Nov-Dec;25(6):500-8. doi: 10.1097/00002371-200211000-00006. J Immunother. 2002. PMID: 12439347 Clinical Trial.

8

Novel treatments for metastatic renal cell carcinoma.

van Spronsen DJ, Mulders PF, De Mulder PH. van Spronsen DJ, et al. Among authors: de mulder ph. Crit Rev Oncol Hematol. 2005 Sep;55(3):177-91. doi: 10.1016/j.critrevonc.2005.04.002. Crit Rev Oncol Hematol. 2005. PMID: 15979888 Review.

9

Novel treatment strategies in clear-cell metastatic renal cell carcinoma.

van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder PH. van Spronsen DJ, et al. Among authors: de weijer kj, de mulder ph. Anticancer Drugs. 2005 Aug;16(7):709-17. doi: 10.1097/01.cad.0000167901.58877.a3. Anticancer Drugs. 2005. PMID: 16027518 Review.

10

Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.

Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E. Steffens MG, et al. Among authors: de mulder ph. Clin Cancer Res. 1999 Oct;5(10 Suppl):3268s-3274s. Clin Cancer Res. 1999. PMID: 10541374 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238 results

Search Page

Filters